Biogen profit drops 22 pct due to Tecfidera-related costs

Forward Pharma A/S

26/01/2017 11:41

Jan 26 (Reuters) - Biogen Inc  BIIB.O  reported a near 22 
percent fall in fourth-quarter income, hurt by higher costs 
related to its top-selling multiple sclerosis drug, Tecfidera. 
    The company said net income attributable fell to $649.2 
million, or $2.99 per share, in the quarter ended Dec. 31 from 
$831.6 million, or $3.77 per share, a year earlier.  urn:newsml:reuters.com:*:nBw27m0jCa 
    Biogen, which is set to spin off its hemophilia business in 
February, said total revenue inched up to $2.87 billion from 
$2.84 billion. 
 
 (Reporting by Natalie Grover in Bengaluru; Editing by Savio 
D'Souza) 
 ((natalie.grover@thomsonreuters.com; within U.S. +1 646 223 
8780, outside U.S. +91 99 1694 7070; Reuters 
Messaging:)(natalie.grover.thomsonreuters.com@reuters.net)) 
 
Keywords: BIOGEN RESULTS/